Century Therapeutics, Inc.
- Open
- 2.42
- Day high
- 2.46
- Day low
- 2.29
- Prev close
- 2.45
- Volume
- 811K
- Mkt cap
- $437M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.7
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$12K over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions accumulating (13F)
Century Therapeutics, Inc. (IPSC) is a Healthcare company listed on NASDAQ. The stock is up 351% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Century Therapeutics, Inc. (IPSC) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IPSC earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.15 | $-0.11 | +26.7% | — | — |
| Mar 12, 2026 | $-0.29 | $-0.25 | +13.8% | — | — |
| Nov 13, 2025 | $-0.39 | $-0.32 | +17.9% | — | — |
| Aug 14, 2025 | $-0.38 | $-0.38 | +0.0% | — | — |
| May 15, 2025 | $-0.31 | $0.89 | +387.1% | $109M | +164.4% |
| Mar 19, 2025 | $-0.45 | $-0.43 | +4.4% | $4M | -91.6% |
| Aug 8, 2024 | $-0.50 | $-0.38 | +24.0% | $771000 | +79.3% |
| May 9, 2024 | $-0.50 | $-0.45 | +10.0% | $855000 | +307.1% |
| Mar 14, 2024 | $-0.56 | $-0.49 | +12.5% | $268000 | -83.9% |
| Nov 9, 2023 | $-0.53 | $-0.55 | -3.8% | $148000 | -88.8% |
| May 11, 2023 | $-0.53 | $-0.53 | +0.0% | $2M | +16.7% |
| Mar 16, 2023 | $-0.59 | $-0.55 | +6.8% | $521000 | -74.0% |
IPSC insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 15, 2026 | Cowan Chadofficer: Chief Scientific Officer | Tax | 358 | $2.24 |
| Jun 15, 2026 | Russotti Gregoryofficer: See Remarks | Sell | 2,584 | $2.23 |
| Jun 15, 2026 | Carr Douglasofficer: SVP Finance & Operations | Sell | 1,654 | $2.23 |
| Jun 15, 2026 | Pfeiffenberger Brentdirector, officer: President and CEO | Tax | 13,849 | $2.24 |
| Jun 12, 2026 | Lee Han Myungdirector | Grant | 74,000 | $2.24 |
| Jun 12, 2026 | Riva Alessandrodirector | Grant | 74,000 | $2.24 |
| Jun 12, 2026 | Quimi Daphnedirector | Grant | 74,000 | $2.24 |
| Jun 12, 2026 | Murphy Martin Patrickdirector | Grant | 74,000 | $2.24 |
| Jun 12, 2026 | Blackwell Kimberlydirector | Grant | 74,000 | $2.24 |
| Jun 9, 2026 | Pfeiffenberger Brentdirector, officer: President and CEO | Tax | 463 | $2.13 |
| Jun 9, 2026 | Carr Douglasofficer: SVP Finance & Operations | Sell | 249 | $2.11 |
| Jun 9, 2026 | Russotti Gregoryofficer: See Remarks | Sell | 524 | $2.11 |
| May 19, 2026 | Pfeiffenberger Brentdirector, officer: President and CEO | Tax | 31,172 | $2.34 |
| May 6, 2026 | Carr Douglasofficer: SVP Finance & Operations | Sell | 264 | $2.34 |
| Apr 10, 2026 | Murphy Martin Patrickdirector | Grant | 88,000 | $0.59 |
Source: IPSC SEC Form 4 filings, latest Jun 15, 2026. For informational purposes only — not investment advice.
See the full IPSC insider & 13F page →Century Therapeutics, Inc. company profile
Overview
Century Therapeutics, Inc. (NASDAQ:IPSC) is a biotechnology company founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company went public in June 2021 and focuses on developing innovative cancer treatments using induced pluripotent stem cell (iPSC) technology. Century Therapeutics represents a next-generation approach to cell therapy, aiming to create "off-the-shelf" treatments that could potentially overcome the limitations of traditional personalized cell therapies.
Business
Century Therapeutics operates in the rapidly evolving field of allogeneic cell therapy for cancer treatment. The company's core innovation lies in using induced pluripotent stem cells (iPSCs) as a starting platform to create engineered immune cells that can fight cancer. To understand this technology, it's helpful to know that traditional cell therapies often use a patient's own immune cells, which are extracted, genetically modified in a laboratory to better recognize and attack cancer cells, then infused back into the same patient. This personalized approach, while effective, is time-consuming, expensive, and not always feasible for critically ill patients. Century's approach is different. They start with iPSCs, which are adult cells that have been reprogrammed to behave like embryonic stem cells, capable of becoming any type of cell in the body. The company engineers these iPSCs to become specialized cancer-fighting immune cells, particularly natural killer (NK) cells and T cells, equipped with chimeric antigen receptors (CARs) that help them identify and destroy specific cancer targets. The company's pipeline includes several product candidates: 1. CNTY-101 - The lead candidate targeting CD19 protein found on B-cell lymphomas using CAR-iNK (CAR-engineered induced NK) cell technology for patients with relapsed or treatment-resistant B-cell lymphoma. 2. CNTY-103 - A CAR-iNK therapy targeting both CD133 and EGFR proteins for treating recurrent glioblastoma, an aggressive form of brain cancer. 3. CNTY-102 - Uses CAR-iT (CAR-engineered induced T cell) technology targeting CD19 and CD79b proteins for B-cell malignancies. 4. CNTY-104 and CNTY-106 - Multi-specific candidates targeting acute myeloid leukemia and multiple myeloma respectively. The company's revenue primarily comes from research collaborations and grants, as none of their therapeutic candidates have reached commercial stage yet.
Revenue model
Century Therapeutics currently operates as a pre-revenue biotechnology company, meaning it doesn't yet generate income from product sales. Instead, the company's limited revenue comes from research collaborations, licensing agreements, and government grants. In 2024, the company reported total revenue of approximately $6.6 million, primarily from collaborative research activities. The company's ultimate business model will be based on product sales of allogeneic cell therapies once they receive regulatory approval. The target customers will be hospitals, cancer treatment centers, and healthcare systems that treat patients with blood cancers and solid tumors. Unlike personalized cell therapies that require individual manufacturing for each patient, Century's "off-the-shelf" approach could potentially offer better margins through economies of scale. Several factors could significantly impact the company's future profitability. Regulatory approval timelines represent the most critical factor - delays in clinical trials or FDA approval could extend the cash-burning phase significantly. Manufacturing costs will be crucial, as the company must demonstrate that their iPSC-derived therapies can be produced at scale more cost-effectively than current personalized approaches. Competition from established cell therapy companies like Gilead Sciences (Kite Pharma) and Bristol Myers Squibb (Juno Therapeutics) could pressure pricing and market share. Reimbursement policies from insurance companies and government healthcare programs will largely determine the commercial viability, as cell therapies typically carry high price points. The company's success will also depend on demonstrating superior or comparable efficacy to existing treatments while potentially offering advantages in manufacturing speed, availability, and cost structure.
Competitive moat
Century Therapeutics' competitive position is built on its proprietary iPSC platform technology, but the strength of this moat remains largely unproven given the company's early stage. The potential advantages of their approach include the ability to create standardized, scalable "off-the-shelf" cell therapies that don't require individual patient cell harvesting and manufacturing, potentially reducing treatment timelines from weeks to days. However, the company faces significant competitive pressures. Established cell therapy companies have substantial head starts in terms of regulatory approvals, manufacturing infrastructure, and clinical experience. Companies like Gilead's Kite Pharma already have approved CAR-T therapies generating billions in revenue, while Century is still in early clinical trials. The scientific and technical risks are considerable. iPSC-derived cell therapies must prove they can match or exceed the efficacy of existing treatments while demonstrating acceptable safety profiles. There's also the risk that the iPSC approach may face unique regulatory hurdles or manufacturing challenges that haven't yet been fully understood. Intellectual property protection provides some defensive moat, but the biotechnology space is highly competitive with numerous companies pursuing similar allogeneic approaches. Large pharmaceutical companies with vastly superior resources could potentially develop competing technologies or acquire more advanced competitors. The company's moat will ultimately depend on execution - successfully advancing candidates through clinical trials, demonstrating superior manufacturing economics, and achieving regulatory approval ahead of or alongside competitors. At this stage, Century's moat is more theoretical than proven, representing significant upside potential but also substantial execution risk.
Risks & safety
Century Therapeutics presents a high-risk investment profile typical of early-stage biotechnology companies, with limited margin of safety. • Cash position and burn rate: The company held $58.4 million in cash and short-term investments as of Q4 2024, with an annual cash burn of approximately $110 million based on 2024 operating cash flow. This suggests roughly 6 months of runway at current burn rates, creating near-term financing pressure. • Debt and solvency: Total liabilities of $191.8 million against total assets of $353.2 million provide some cushion, but the company's debt-to-equity ratio of 0.33 indicates moderate leverage for a development-stage company. • Valuation metrics: With a market cap around $53 million and negative earnings, traditional valuation metrics are not meaningful. The company trades below book value (P/B ratio of 0.49), suggesting potential asset value but also market skepticism. • Revenue generation: Minimal revenue of $6.6 million annually provides no meaningful support for current operations, making the company entirely dependent on capital markets for funding. • Clinical stage risks: All product candidates are in early clinical development, with regulatory and efficacy risks that could render the entire pipeline worthless. The margin of safety is essentially non-existent from a traditional value investing perspective, as the company's value depends entirely on successful execution of unproven therapies in a highly competitive and regulated market.
Recent development
Based on the available financial data, Century Therapeutics has been focused on advancing its iPSC-derived cell therapy platform through clinical development. The company has maintained a consistent research and development focus, with annual operating cash outflows exceeding $100 million, indicating substantial investment in advancing their pipeline candidates. The most significant development appears to be the progression of their lead candidate CNTY-101 for B-cell lymphoma, along with advancement of their broader pipeline including candidates for glioblastoma (CNTY-103) and other hematological malignancies. The company has been building out their manufacturing capabilities and clinical infrastructure to support multiple concurrent programs. Recent financial results show the company has been managing its cash resources while continuing to invest heavily in research and development. The unusual positive net income and EBITDA reported in Q1 2025 ($76.6 million and $77.4 million respectively) compared to consistent losses in previous quarters suggests a significant one-time event, possibly related to asset sales, licensing deals, or accounting adjustments, though specific details are not available from the financial summaries. The company has maintained its focus on the allogeneic cell therapy approach, positioning itself to potentially offer advantages over personalized cell therapies through standardized manufacturing and reduced treatment timelines. However, without detailed earnings call transcripts, specific strategic pivots or partnership developments cannot be definitively characterized.
IPSC company profile · for informational purposes only — not investment advice.
Track IPSC with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free